

## Makers Laboratories Limited

Regd. Office : 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(Rs. In Lacs)


Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	1,124.70	1,736.49	1,013.48	3,886.08	3,867.00	4,662.50
II	Other Income	(1.59)	6.97	53.60	9.82	159.91	257.17
III	<b>Total Income (I + II)</b>	<b>1,123.11</b>	<b>1,743.46</b>	<b>1,067.08</b>	<b>3,895.90</b>	<b>4,026.91</b>	<b>4,919.67</b>
IV	<b>Expenses:</b>						
	a) Cost of materials consumed	176.68	225.50	301.01	630.69	1,101.04	1,283.34
	b) Purchases of stock-in-trade	834.92	699.90	316.45	1,749.82	1,056.15	1,588.38
	c) Changes in inventories of finished work-in-progress and stock-in-trade	(355.24)	150.40	42.76	(59.67)	283.72	8.09
	d) Employee benefits expense	184.35	207.30	176.02	584.20	542.42	701.29
	e) Finance Cost	19.04	17.93	4.33	43.83	22.81	25.41
	f) Depreciation and amortisation	48.08	50.97	38.17	136.81	111.36	150.28
	g) Other expenses	262.51	345.45	227.80	864.99	711.20	861.26
	<b>Total Expenses (IV)</b>	<b>1,170.34</b>	<b>1,697.45</b>	<b>1,106.54</b>	<b>3,950.67</b>	<b>3,828.70</b>	<b>4,618.05</b>
V	<b>Profit / (Loss) before tax (III - IV)</b>	<b>(47.23)</b>	<b>46.01</b>	<b>(39.46)</b>	<b>(54.77)</b>	<b>198.21</b>	<b>301.62</b>
VI	<b>Tax Expense</b>						
	Current Tax	-	-	(15.70)	-	50.00	76.70
	Deferred Tax (Asset) / Liability	(31.81)	14.33	(0.80)	(9.15)	(17.98)	(19.96)
VII	<b>Net Profit / (Loss) after tax (V-VI)</b>	<b>(15.42)</b>	<b>31.68</b>	<b>(22.96)</b>	<b>(45.62)</b>	<b>166.19</b>	<b>244.88</b>
VIII	<b>Other Comprehensive Income</b>	<b>206.46</b>	<b>(24.24)</b>	<b>116.27</b>	<b>122.05</b>	<b>133.09</b>	<b>287.77</b>
	a) Items that will not be reclassified to profit & loss	233.01	(25.91)	124.39	139.39	142.47	321.61
	Less: Tax expenses thereon	26.55	(1.67)	8.12	17.34	9.38	33.84
IX	<b>Total Comprehensive Income after tax (VII + VIII)</b>	<b>191.04</b>	<b>7.44</b>	<b>93.31</b>	<b>76.43</b>	<b>299.28</b>	<b>532.65</b>
X	Paid-up equity share capital (Face value of Rs.10/- each)	491.70	491.70	491.70	491.70	491.70	491.70
XI	Other Equity						3,678.46
XII	Earnings per share (of Rs.10/- each) - Not annualised :						
	Basic & Diluted	(0.31)	0.64	(0.47)	(0.93)	3.38	4.98

**Notes:**

- 1 The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on February 6, 2020.
- 2 The statutory auditors have carried out a limited review of the financial results and have issued their unmodified report thereon.
- 3 The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- 4 With effect from April 01, 2019 the Company has adopted Ind AS 116, 'Leases', in respect of new lease entered during the period. There were no existing arrangements which were covered by Ind AS 116.
- 5 The Company has only one reportable segment viz. 'Pharmaceuticals'.
- 6 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

By Order of the Board  
For Makers Laboratories Limited

*Smit Binkh*  
Smit Binkh  
Wholetime Director  
(DIN 00400079)



Place : Mumbai,  
Date : February 6, 2020

